戻る Agenda
Session 5: Content of a US Risk Evaluation & Mitigation Strategy (REMS)
Session Chair(s)
Carla Barrett, PHARMD
Vice President, Global Risk Management
Novavax, United States
- This session will review the requirements for a REMS in the US, including discussions on shared system REMS. The FDA REMS website will be demonstrated.